Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system

Add time:07/16/2019    Source:sciencedirect.com

Background and aimsMolecular basis of abdominal pain in IBD is not fully characterized. Serotonin (5-HT) increases visceral pain severity and contributes to exacerbation of inflammation. Moreover, it is well established that decreased anandamide (AEA) signaling in the gut increases visceral pain severity. The aim of this study was to investigate the interplay between 5-HT and endocannabinoid signaling in colitis.

We also recommend Trading Suppliers and Manufacturers of Docosahexaenoyl Serotonin (cas 283601-58-1). Pls Click Website Link as below: cas 283601-58-1 suppliers

Prev:Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract
Next:Synthesis of a water soluble boron neutron capture therapy agent: 1-amino-3-[2-(7-{3-[2-(2-hydroxymethyl-ethoxy)-1-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)ethoxy]propyl}-1,7-di-carba-closo-dodecaboran-1-yl)ethyl]cyclobutanecarboxylic acid)